By Emmanuel Oluebube, Correspondent UK

The multinational pharmaceutical company, Hikma Pharmaceuticals PLC (Hikma), has  announced that it has entered into an exclusive licensing agreement with Almirall S.A., a global biopharmaceutical company, to commercialise FinjuveTM in certain Middle East and North Africa (MENA) markets.

FinjuveTM is a finasteride spray that is approved in Italy, Germany, Luxembourg and Portugal for the treatment of androgenetic alopecia.

Under the terms of the licensing agreement, Hikma will be responsible for the registration and commercialisation of the product in certain MENA markets and Almirall will be responsible for product supply.

Hikma’s Executive Vice Chairman and President of MENA Mazen Darwazah, said, “We are excited to partner with Almirall and bring FinjuveTM to our androgenetic alopecia patients in MENA, broadening the range of treatment choices available. This collaboration augments our growth in dermatology, a key therapeutic area for Hikma, and adds a differentiated product to our portfolio. We look forward to working with Almirall.”